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Abstract
Introduction and hypothesis The aim of this study was to
evaluate the results of conservative treatment of urodynamic
stress urinary incontinence (SUI) using transvaginal electrical
stimulation with surface-electromyography-assisted biofeed-
back (TVES+sEMG) in women of premenopausal age.
Methods One hundred and two patients with SUI were divid-
ed into two groups: active (n=68) and placebo (n=34) TVES+
sEMG. The treatment lasted for 8 weeks and consisted of two
sessions per day. Women were evaluated before and after the
intervention by pad test, voiding diary, urodynamic test, and
the Incontinence Quality of Life Questionnaire (I-QOL).
Results Mean urinary leakage on a standard pad test at the
end of 8th week was significantly lower in the active than
the placebo group (19.5±13.6 vs. 39.8±28.5). Mean urinary
leakage on a 24-h pad test was significantly reduced in the
active group at the end of 8th and 16th weeks compared
with the placebo group (8.2±14.8 vs. 14.6±18.9 and 6.1±
11.4 vs. 18.2±20.8, respectively). There was also a signif-
icant improvement in muscle strength as measured by the
Oxford scale in the active vs the placebo group after 8 and
16 weeks (4.2 vs 2.6 and 4.1 vs 2.7, respectively). No
significant difference was found between groups in
urodynamic data before and after treatment. At the end of
8th week, the mean I-QOL score in the active vs the placebo
group was 78.2±17.9 vs 55.9±14.2, respectively, and at the
end of 16th week 80.8±24.1 vs. 50.6±14.9, respectively.
Conclusion Our study showed that TVES+sEMG is a trust-
worthy method of treatment in premenopausal women with
SUI; however, its reliability needs to be established.
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Introduction
Urinary incontinence (UI) affects 10–30 % of women aged
15–64 years. Stress urinary incontinence (SUI) is the most
common type of UI and is manifested by uncontrolled loss of
urine due to physical exertion. The predisposing risk factors
include attenuation of connective-tissue elasticity, vaginal de-
livery, obesity, hard physical work, and being elderly [1].
There are two types of commonly used SUI outcome mea-
sures: objective [cough stress test, pad test, and urodynamic
evaluation) and subjective (patient self-assessment, validated
questionnaires, voiding diaries, patient satisfaction, and qual-
ity of life (QOL)] [2]. A number of treatments for SUI are
available, with the primary aim of reducing the occurrence of
incontinence episodes and therefore limiting the impact of the
disorder on an individual’s QOL [3].
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Physical therapies involving pelvic floor muscle training
with or without other treatments, such as vaginal cones, bio-
feedback, and electrical stimulation (ES), are the core conser-
vative and preventive treatments. Most studies present effect
rates as combined cure and symptom improvement rates,
mostly counting those women who improved by ≥50 % on
the primary outcome measure of effect. Short-term effect rates
may exceed 70 %, whereas long-term effect rates may reach
50 % when adherence is maintained [4, 5]. Many authors
report that symptoms returned or increased after therapy had
ended and concluded that declining adherence levels were
probably the most important cause for declining long-term
effect rates [6–8].
ES is a conservative treatment option described more
than 50 years ago [9]. The mechanism of action of ES was
initially investigated in animal models, where it caused
bladder relaxation by inhibiting the parasympathetic motor
neurones. Other studies showed that ES causes contractions
of the pelvic floor, increasing the number of muscle fibers
with rapid contraction that are responsible for continence in
situations of stress [10].
Transvaginal electrical stimulation (TVES) is the nonpainful
application of electrical current using a sensor with electrodes
placed in the vagina to directly stimulate the pelvic floor
muscles to contract and relax. Stimulation may help strengthen
the muscles and ease SUI and can also help control urgency by
acting on the nerves and decreasing bladder irritability [11, 12].
The ideal electrical parameters for pelvic floor stimulation have
not yet been well established. The few randomized clinical
trials to date advocate using 20–50 Hz for SUI. The equipment
is used transvaginally in daily sessions for 15–30 min at the
maximum intensity individually tolerated for a variable period
of 4–12 weeks [13, 14]. The results of randomized controlled
trials evaluating the effect of (ES) to treat SUI are conflicting.
There is a need for more randomized controlled trials with
sufficient sample sizes; use of sensitive, reproducible, and valid
outcome measures; and optimal stimulation parameters [15].
Surface EMG (sEMG) is one method used to evaluate
SUI treatment outcome by recording the change in voltage
over the muscle fiber membrane that initiates the contrac-
tion. Control of the muscle contraction is mediated via nerve
impulses in the motor nerves. For skeletal muscles, there is
generally a relationship between EMG activity and force,
which means that higher activity levels correspond to an
increase in force [16].
Biofeedback involves using electrodes to transduce mus-
cle potentials into auditory or visual signals; patients learn to
increase or decrease voluntary muscle activity. Biofeedback
is useful to promote correct control of contraction and
visualization, because many women cannot at first contract
their pelvic floor muscles and require some type of motiva-
tion. Biofeedback treatments are safe and effective interven-
tions that should be more readily available to patients as a
first-line treatment for voiding dysfunction. Patient educa-
tion may take time but has higher long-term success and
makes the patient more responsible and less passive regard-
ing their condition [17].
Although strong evidence suggests that TVES is effective
for reducing SUI symptoms, data on adjunctive techniques
are less consistent. Studies are significantly heterogeneous
in methodology and follow-up, making conclusions diffi-
cult. Thus, the aim of this study was to evaluate the results
of conservative SUI treatment using TVES with sEMG-
assisted biofeedback in women of premenopausal age.
Materials and methods
One hundred and two women with urodynamic SUI who
underwent treatment at our departments from January 2008
to April 2012 were enrolled in this study. Standardized assess-
ment was performed at enrolment, taking into consideration a
comprehensive urogynecological history, urodynamic assess-
ment including uroflowmetry and cystometry, bacteriological
examination, and pad tests. The protocol was previously ap-
proved by the Bioethical Committee of the Medical Univer-
sity of Bialystok (R-I-002/143/2009), and all women gave
their written consents.
Major exclusion factors were patients with chronic de-
generative diseases that would affect muscular and nerve
tissues, presence of any degree of pelvic organ prolapse
(POP), active or recurrent urinary tract infections (UTI),
vulvovaginitis, atrophic vaginitis, diabetes mellitus, neuro-
logical disease, psychiatric illness, use of medication affect-
ing micturition, history of surgical or pharmaceutical
treatment of SUI, chronic debilitating disease such as renal
failure, and those with cardiac pacemakers. We also exclud-
ed patients with intrinsic sphincteric deficiencies identified
by the Valsalva leak-point pressure ≤60 cmH20 measure-
ment in the sitting position with a volume of 250 ml in the
bladder and/or a urethral closure pressure ≤20 cmH20 in the
sitting position at maximum cystometric capacity.
Participants were taught skills and strategies for preventing
incontinence and suppressing urge. This included education
about normal bladder control, lifestyle interventions such as
weight reduction, relieving constipation, smoking cessation,
caffeine reduction, fluid management, wearing nonrestrictive
and easily removed clothing, reducing emotional stress, and
correcting faulty habit patterns of frequent urination by
suggesting distraction and avoidance techniques. Advice on
good voiding position was also provided. In addition, an
information booklet was provided to reinforce this
information.
The severity of UI can be assessed by various methods,
such as a urinary symptoms questionnaire, frequency/volume
chart (bladder diary), QOL questionnaire, or pad tests. A 7-
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day bladder diary provides the means for assessing voiding
frequency and volume, together with the frequency of leaks at
0, 8, and 16 weeks.
During initial examination, a POP and pelvic floor dys-
function assessment was performed, as previously de-
scribed, with the patient supine and after voiding [18].
Assessment of pelvic floor muscle strength was performed
with vaginal palpation; the woman in the lithotomy position
used one finger with the two distal phalanges inside the
introitus vagina. One gynecologist per department should
examine and palpate the external and internal vaginal and
rectal muscles for function, pain, strength, coordination, and
endurance for standardizing the methodology. The effort
was graded with the Oxford score (0 nil; 1 flicker; 2 weak;
3 medium, with slight lift of the examiners finger and no
resistance; 4 strong, sufficient to elevate the examiner’s
finger against light resistance; 5 very strong, sufficient to
elevate the examiner’s finger against strong resistance) [5].
Next, the bladder was drained to obtain a postvoid residual,
and the s bladder was then retrograde filled to a volume of
300 ml or maximal capacity (if that occurred prior to 300 ml).
The patient was then cued to cough and perform a Valsalva
maneuver while supine. If no urine leakage was observed, the
patient was asked to perform the same maneuvers while
standing. The cough stress test was considered positive if
any leakage was noted with cough or Valsalva [19].
Uroflowmetry (Ellipse Andromeda System, Germany) was
performed on all participants. Each participant was asked to
attend the session with a comfortably full bladder to perform a
free-flow uroflowmetry. In order to carry out the test, it was
necessary to gain an artificial standardized fill of 250 ml using
a size-12 Foley urethral catheter at a maximum filling rate of
20 ml per minute. After emptying the patient’s bladder with a
catheter, the 20-min pad test by infusion of 250 ml distilled
water in the bladder was performed after the urodynamic
study. Each patient returned to a standing position, with a
preweighed perineal pad placed inside the underwear. Each
patient was asked to cough ten times, bear down ten times, do
ten deep knee bends, jump up and down in place ten times,
wash her hands under cold water for 1 min, walk up and down
five stairs ten times, walk in the hall for 10 min, and then
return for removal of the pad (Bella Sp. z o.o., Torun, Poland).
The pad was then weighed, and the net weight was calculated
by subtracting the original dry weight to achieve a measure of
the total urine lost during the 20-min exercise. A pad weight
result was considered positive if a leakage >1 g was noted;
pads were weighed on a precision laboratory balance Acculab
VI-1200 (Bradford, MA, USA) [20].
Patients with urodynamically confirmed SUI were ran-
domized using a computer-generated random sequence giv-
en in sealed envelopes to patients in group 1 [active (n=68)]
or group 2 [placebo (n=34)] TVES with sEMG-assisted
biofeedback. In a previous study with 24 patients, the final
sample size was calculated as 102 patients for a power of
80 % and a 2:1 ratio (68 and 34, respectively). Patient
distribution was chosen to better evaluate the proposed
technique. One hundred and nineteen individuals were
screened for eligibility: 107 were eligible, five of whom
withdrew before completion of assessments. Thus, 102 were
recruited. Group assignment was enclosed in sequentially
numbered, sealed envelopes by a person not involved in the
study. The physiotherapist and physician carrying out the
assessment were unaware of which treatment group the
patient was in. To minimize the likelihood of assessor bias,
participants were asked not to discuss their treatment and/or
reveal any information on group allocation to the principal
investigator doing the assessments. Participants were sched-
uled to attend clinic visits. All interventions were performed
by gynecologists and competent physiotherapists. Screen-
ing, outcome assessments, and weekly visits were carried
out at hospital sites offering identical facilities.
In group 1 TVES, was provided with the addition of sEMG
biofeedback. EMG records muscle bioelectrical activity and
measures electrical correlation of the muscle contraction. Vag-
inal and surface electrodes can be used to provide an overview
of the contraction and relaxation phases of pelvic floor muscle
activity. EMG biofeedback assessment used a NeuroTracTM
ETS unit (Verity Medical Ltd, Hampshire, UK). A vaginal
electrode, VeriProbe (Verity Medical), was applied according
to the manufacturer’s instructions with Zelpol lubricating
couplant (Centrum Medicum, Poland), and stimulation pa-
rameters and patient-acceptable sensitivity thresholds were
determined. The device combines biofeedback and (ES), with
effective monitoring of compliance with treatment and perfor-
mance. Patient position, accuracy of electrode placement,
exact warmup period, and time of day were all recorded.
The regimen included a warmup of five contractions and five
relaxations, followed by a contraction/relaxation assessment.
Participants were encouraged to selectively contract and relax
their pelvic floor muscles with the assistance of visual and
auditory feedback.
Patients in group 1 were provided with active TVES with
sEMG. Parameters of muscle stimulation were adapted for
each participant: frequency ranged from 10 to 40 Hz, impulse
width from 200 to 250 μs, and runtime/decontraction in
configuration of 15 s/30 s for 20 min. The treatment lasted
for 8 weeks and was performed twice a day. The introduction
took place in the clinic, and the actual treatment was
performed by patients at home, with a gradual increase to a
daily maximum of 40 min. At each weekly visit, compliance
was monitored by means of a concealed button on the
NeurotracTM ETS unit, and the unit was reprogrammed week-
ly, as appropriate.
Participants in group 2 were provided with a placebo set to
parameters proven to have no physiological effect. The same
type of electrode and hand-held unit as described for TVES
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with sEMG biofeedback was used in the clinic and for home
application. Preset parameters were a frequency of 2 Hz, a
pulse width of 50 μs, 2 s of stimulation, and 60 s of no
stimulation, with a ramp of 8 s. As with group 1, the introduc-
tion took place in the clinic, and patients used issued devices at
home, with a gradual increase to a daily maximum of 40 min.
Treatment continued until participants had completed 8 weeks
with the assigned device. At this point, a posttreatment assess-
ment identical to the intake assessment was performed. Par-
ticipants underwent three 24-h pad tests using Bella Normal
sanitary pads. For each test (week 0, 8, and 16), five pads each
contained in their own sealable plastic bag were weighed and
given to participants. Women were asked to wear the pads for
24 h: one pad at a time for a maximum of 6 h except for the
pad worn during the night’s sleep, which could be worn all
night. After usage, the pad, its wrapper, and adhesive strips
were returned to their plastic bag and sealed to prevent evap-
oration. The two pad tests were to be completed within a week
and returned to the clinic within the following week prior to
initiation of the new treatment. The pads were reweighed, and
the urine lost during each 24-h period was calculated. If the
wrapper and adhesive strips were not returned, pad weight
results were adjusted to account for their weight. Pre- and
postpad weights were determined using the same beam bal-
ance scales with accuracy to 0.1 g. The 24-h pad test was
considered positive if a weight exceeded 8 g [19, 21].
Fig. 1 Recruitment and
progress of participants
throughout the trial
1634 Int Urogynecol J (2013) 24:1631–1638
All study participants were also asked to complete the
validated Incontinence Quality of Life (I-QOL) question-
naire containing one section. A score of 100 represented the
best possible QOL, and 0 represented the worst possible
QOL. Valid and reliable outcome measures were recorded at
weeks 0 (baseline), 8, and 16. The I-QOL contains 22
negatively framed items, each with a five-point Likert-type
response scale (1 extremely, 2 quite a bit, 3 moderately, 4 a
little, 5 not at all). The I-QOL was scored according to the
instructions [22]. In addition to yielding a total score, the I-
QOL consists of the following three domain scores: avoid-
ance and limiting behaviors (eight items), psychosocial im-
pacts (nine items), and social embarrassment (five items).
The I-QOL total and subscale sum scores are transformed
onto a 0–100 scale for greater interpretability, with the
higher scores representing greater QOL. Once the I-QOL
was scored and plotted, variations in mean scores were
noted across the language versions [23].
Statistical analysis was performed using Statistica software
version 9.0PL (StatSoft, Inc., StatSoft Polska Sp. z o.o.,
Poland). A chi-square test was used to evaluate the relation-
ship between categorical variables. Fisher’s exact test was
used to determine significance between groups. The Mann–
Whitney U test was used for comparison of continuous vari-
ables between groups. Comparisons within each group were
carried out using the Wilcoxon signed rank test. A p value <
0.05 was considered statistically significant.
Results
One hundred and nineteen individuals with SUI were screened
(Fig. 1). Twelve failed to meet the inclusion/exclusion criteria,
and a further five were unwilling to take part in the study.
There were no statistically significant differences detected in
demographic data and clinical characteristics between groups
(Table 1).
During the 8 weeks of active treatment, four participants in
group 1 withdrew completely because the protocol was found
to be too demanding (n=2) or they were unable to use the
stimulator at home (n=2). Five participant in tgroup 2
discontinued because they used other treatments during the
trial (n=3), change of work (n=1), and death in the family
(n=1). The overall scores on the I-QOL are given in Table 2.
At baseline the mean I-QOL score in group 1 was 61.8 ±13.4
and in group 2 66.2±23.8 (p=0.241). At the end of 8th week,
the mean I-QOL score in group 1 was 78.2±17.9 and in group
2 55.9±14.2 (p=0.004); at the end of 16th week, scores were
80.8±24.1 vs. 50.6±14.9, respectively (p<0.001). In group 1,
there was a significant reduction in subjective perception of
the impact of incontinence during the treatment period.
At baseline, a standard 20-min pad tests showed no signif-
icant differences between groups 1 and 2 (25.6±27.1 vs.
27.9±29.1; p=0.310). Mean urinary leakage on a standard
pad test at the end of 8th week was significantly lower in the
group 1 compared with the group 2 (19.5±13.6 vs.
Table 1 Selected demographic
and baseline clinical characteris-
tics for each group
Data presented as mean
± standard deviation, data in pa-
renthesis are percentages. De-
notes overall comparison among
groups using chi-square test and
independent samples t test
Variables Group 1 n=64 Group 2 n=29 P value
Age 46.9±6.8 45.6±7.9 0.591
Body mass index 24.9±3.7 25.1±2.8 0.197
Smoker (%) 7 (10.9) 4 (13.8) 0.355
Durations of symptoms (year) 6.0±3.9 5.9±4.9 0.260
Pregnancy 3.1±2.1 3.8±1.8 0.750
Vaginal delivery 3.5±2.6 3.1±2.7 0.902
Cesarean delivery 0.5±0.4 0.5±0.9 0.432
Table 2 Subjective and objec-
tive variables before and after
treatment
Data presented as mean±stan-
dard deviation. Denotes overall
comparison between groups
using Mann–Whitney U test
Variables Group 1 n=64 Group 2 n=29 P value
I-QOL (baseline) 61.8 (±13.4) 66.2 (±23.8) 0.241
I-QOL (8 weeks) 78.2 (±17.9) 55.9 (±14.2) 0.004
I-QOL (16 weeks) 80.8 (±24.1) 50.6 (±14.9) < 0.001
20-min pad test (g) (baseline) 25.6 (±27.1) 27.9 (±29.1) 0.310
20-min pad test (g) (8 weeks) 19.5 (±13.6) 39.8 (±28.5) 0.003
24-h pad test (g) (baseline) 12.4 (±18.2) 13.9 (±16.3) 0.344
24-h pad test (g) (8 weeks) 8.2 (±14.8) 14.6 (±18.9) 0.004
24-h pad test (g) (16 weeks) 6.1 (±11.4) 18.2 (±20.8) 0.002
Oxford score (baseline) 2.9 2.8 0.339
Oxford score (8 weeks) 4.2 2.6 <0.001
Oxford score (16 weeks) 4.1 2.7 <0.001
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39.8±28.5; p=0.003). Mean urinary leakage on a 24-h pad
test was significantly reduced in group 1 at the end of weeks
8 and 16 compared with group 2 (8.2±14.8 vs. 14.6±18.9;
p=0.004 and 6.1±11.4 vs. 18.2±20.8; p=0.002, respectively).
There was also a significant improvement in muscle strength
as measured by the Oxford scale in group 1 compared with
group 2 after 8 and 16 weeks (4.2 vs 2.6 and 4.1 vs 2.7,
respectively; p<0.001) (Table 2). On the basis of the 7-day
voiding-diary logs, we there was no change in voiding fre-
quency between groups. The severity of urinary symptoms,
such as frequency of urine loss, occurrence of nocturia, and
number of pads used, significantly decreased in group 1
compared with group 2 at 8 and 16 weeks (Table 3).
No significant difference was found between groups in
urodynamic data before and after treatment (Table 4).
Twenty-five women (39 %) were objectively cured on the
standard pad test, and a cure was defined as ≤1 g of leakage
with a standardized bladder volume. In group 2, objective
cure was not achieved. Subjectively, 29 (45.3 %) of patients
in group 1 considered themselves cured, 12 (18.7 %) im-
proved, 17 (26.6 %) unchanged, and six (9.4 %) worse. In
group 2, subjective cure was reported by two (6.9 %),
improvement by four (13.8 %), no change by 14 (48.3 %),
and worsening by nine (31 %). There were no side effects
reported in group 2; in group 1, four participants reported
smarting (three bleeding, one discomfort).
Discussion
For patients with SUI, urine leakage and loss of muscle
strength are classified as impairments of body function, with
significant socioeconomic and QOL impact. SUI imposes
significant restrictions on patients in regards to social activ-
ities, travel, recreation, and personal relationships. Several
conservative treatment options are available for managing
Table 3 Seven-day voiding di-
ary before and after treatment
Data presented as mean±stan-
dard deviation. P value deter-
mined by Wilcoxon signed rank
test.
Variables Group 1 n=64 Group 2 n=29 P value
Voiding frequency(baseline) 48.4 (±19.8) 46.8 (±16.8) 0.341
Voiding frequency (8 weeks) 47.2 (±12.4) 48.6 (±18.6) 0.224
Voiding frequency (16 weeks) 48.2 (±16.8) 49.2 (±19.4) 0.327
Frequency of urine loss (baseline) 16.4 (±18.4) 14.8 (±16.2) 0.311
Frequency of urine loss (8 weeks) 6.7 (±5.3) 16.2 (±14.7) <0.001
Frequency of urine loss (16 weeks) 6.2 (±5.8) 17.2 (±15.6) <0.001
Occurrence of nocturia (baseline) 12.4 (±10.7) 13.8 (±11.4) 0.283
Occurrence of nocturia (8 weeks) 6.7 (±4.7) 14.6 (±12.4) 0.012
Occurrence of nocturia (16 weeks) 6.8 (±4.9) 15.4 (±12.9) 0.002
No. of pads used (baseline) 9.2 (±7.4) 8.7 (±6.8) 0.324
No. of pads used (8 weeks) 3.4 (±4.2) 9.2 (±7.6) 0.022
No. of pads used (16 weeks) 3.8 (±4.8) 9.1 (±6.9) 0.024
Table 4 Urodynamic data be-
fore and after treatment
Data presented as mean±stan-
dard deviation. Data in paren-
thesis are percentages. Denotes
overall comparison among
groups using Mann–Whitney U
test
Cystometry Group 1 n=64 Group 2 n=29 P value
Volume at first desire to void (ml) baseline 134.6±51.6 138.2±57.1 0.911
Volume at first desire to void (ml) 8 weeks 149.6±69.3 141.1±49.2 0.07
Maximum cystometric capacity (ml) baseline 536.7±149.8 528.2±149.8 0.777
Maximum cystometric capacity (ml) 8 weeks 589.2±149.7 487.2±111.9 0.223
Postmicturition residual (ml) baseline 8.1±3.4 10.8±5.1 0.801
Postmicturition residual (ml) 8 weeks 5.1±4.0 11.8±7.8 0.693
No. (%) with negative stress test (urodynamic) 8 weeks 13(20.3) 2(6.9)
Functional urethral length (cm) baseline 2.8±0.9 2.7±0.8 0.466
Functional urethral length (cm) 8 weeks 2.6±0.5 2.5±0.5 0.560
Maximum urethral closure pressure (cm H2O) baseline 53.8±8.2 52.9±7.1 0.579
Maximum urethral closure pressure (cm H2O) 8 weeks 55.9±6.9 54.9±9.8 0.518
Maximum flow rate ml/s baseline 29.4±9.1 27.8±6.8 0.714
Maximum flow rate ml/s 8 weeks 30.3±10.1 28.4±9.2 0.105
Average flow rate ml/s baseline 15.9±9.4 16.1±9.5 0.911
Average flow rate ml/s 8 weeks 17.5±8.2 18.1±10.1 0.188
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SUI [24, 25]: TVES is one nonsurgical approach. Its pur-
pose is to increase urethral resistance by strengthening the
pelvic floor musculature and, consequently, improving in-
continence associated with stress. It is an effective and safe
therapy, but results vary widely from study to study, even
when treatment uses the same device. Comparative analyses
among standard urodynamic parameters before and after
several sessions of (ES) do not clearly explain the influence
of the vaginal electrode on outcomes [26].
In our study, no significant difference was found between
groups in urodynamic data before and after treatment. There-
fore, as with Resplande et al. [26], we concluded that, at least
acutely, (ES) did not modify some baseline cystometry pa-
rameters and did not modify the mechanical presence of the
vaginal electrode when turned off. However, it is important to
remember that the correlation between clinical improvement
and urodynamic changes remains controversial [14].
In patients with SUI, pelvic floor (ES) is suggested to act
at the muscular level by activating the pudendal nerve motor
efferents and through reflex activation. Stimulation would
promote successive contractions of the pelvic floor muscles,
thus invigorating and strengthening such muscle fibers [10,
27]. Because the pudendal nerve is an efferent nerve for
both the pelvic floor muscles and the external urethral
sphincter, damage to it can generate weakness of the pelvic
floor, resulting in POP, and relaxation of the external ure-
thral sphincter, resulting in SUI [28].
Comparison between published studies of TVES is diffi-
cult because different therapies and different outcome vari-
ables are used. It is reported that there is strong evidence in
favor of TVES or TVES with sEMG versus no treatment for
SUI in women [5, 29]. It is known that discontinuation of a
program will result in loss of any therapeutic effect within
4–6 weeks, whereas continuation of daily treatment for 3–
6 months is essential to preserve the achieved muscle
strength [30].
Results of our study demonstrate that TVES with sEMG
increased muscle strength most during the first 2 months of
treatment and was well preserved at month 4. This is in line
with findings of pad tests and subjective I-QOL question-
naires. We found that this intervention is of great importance
if used at the beginning of therapy and in the follow-up
period and it is highly reproducible. It makes it easier for the
physiotherapist to teach isolated pelvic floor muscles con-
traction, facilitates goal setting, and helps keep the patient
highly motivated. We also show that compliance was ho-
mogeneous and satisfactory, probably due to the clear and
consistent directions and the characteristics of the equip-
ment. The subjective success rate of those therapies was
approximately 45 % and the objective (pad test) rate ap-
proximately 39 %. Treatment was very well tolerated, and
few adverse events could be correlated with treatment. The
significant improvements in QOL demonstrated in this
study are important because they help us to understand the
clinical relevance in alterations in pad tests and voiding
diary. Such an outcome was expected, as by receiving visual
feedback on the intensity and contraction waveform, patients
have a chance to correct themselves. The addition of ES
triggered by the pressure signal aims to create an association
between the voluntary attempts to produce a contraction and
an actual contraction that is guaranteed by electrical stimulus.
In this study, a physiotherapist supervised all sessions in the
clinic and increased the intensity of electrical impulses. This
engagement was probably responsible for the high rate of
compliance with treatment and the favorable outcomes based
on subjective and objective measures.
QOL has become an important outcome measure in clin-
ical trials dealing with SUI treatment. In our study, we
observed a significant improvement in QOL of treated wom-
en after the intervention, particularly with regard to factors
related to limitations (in physical and social activities) and to
severity measures. Whereas QOL scores differed in some
countries (i.e., lower scores in Poland and Slovakia, and higher
scores in Greece and The Netherlands), I-QOL score compo-
nent trends remained very similar. The differences are more
than likely related to differences in population characteristics
rather than measurement errors. Reliability, using Cronbach’s
alpha, was confirmed in all language versions, where high
internal consistency was demonstrated by alpha values above
0.70. Similarly, test–retest reliability showed the I-QOL to be
stable over time, with intraclass correlation coefficient (ICC)
values all greater than the recommended 0.70 [23].
In conclusion, this study shows that TVES with sEMG is
a trustworthy method for treating premenopausal women
with SUI; however, reliability needs to be established.
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